Capivasertib
A kinase inhibitor that targets AKT, a key protein in the PI3K signaling pathway frequently activated in breast and other cancers. It is used in combination with fulvestrant to treat hormone receptor-positive, HER2-negative breast cancer with specific PI3K pathway mutations following disease progression. It works by blocking cellular survival and growth signals downstream of PI3K.
Moleküler Ağırlık
428,9000 g/mol
LogP
1,70
TPSA
120,00 Ų
Lipinski RO5
Geçer
Terapötik Alanlar
Etki Mekanizması
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
2D Yapı
Cite this structure
Embed this structure
SMILES
NC1(C(=O)N[C@@H](CCO)c2ccc(Cl)cc2)CCN(c2nc[nH]c3nccc2-3)CC1
InChI
InChI=1S/C21H25ClN6O2/c22-15-3-1-14(2-4-15)17(6-12-29)27-20(30)21(23)7-10-28(11-8-21)19-16-5-9-24-18(16)25-13-26-19/h1-5,9,13,17,29H,6-8,10-12,23H2,(H,27,30)(H,24,25,26)/t17-/m0/s1
Molecular Formula
C21H25ClN6O2
HBD / HBA
4 / 6
Döndürülebilir Bağlar
6
Ağır Atomlar
30
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Sıkça Sorulan Sorular
A kinase inhibitor that targets AKT, a key protein in the PI3K signaling pathway frequently activated in breast and other cancers. It is used in combination with fulvestrant to treat hormone receptor-positive, HER2-negative breast cancer with specific PI3K pathway mutations following disease progression. It works by blocking cellular survival and growth signals downstream of PI3K.
Targets the HER2 (ErbB2) receptor tyrosine kinase, blocking HER2-mediated signaling that drives proliferation in HER2-overexpressing cancer cells.
Yes, Capivasertib is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL2325741. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 25227436. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="capivasertib"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/capivasertib/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/capivasertib/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/capivasertib/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="capivasertib"></drugfyi-drug>